Maxcyte
MXCT· Services· Fiscal year ends in December
CEO pay in FY2025Stock -62.7% in FY2025
Maher Masoud is the CEO of Maxcyte and was paid $2.7M in FY2025 (Dec), down 26%.
Pay$100 in the stock at the end of FY21 → $15
Executives3
See all- 1Maher MasoudPresident and Chief Executive OfficerFY2025
- 2Douglas SwirskyFormer Chief Financial OfficerFY2025
- 3Ali SoleymannezhadFormer Chief Commercial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allMaxcyte paid its 3 named executives $5.0M in total in FY2025 (Dec). CEO Maher Masoud was paid $2.7M of that.
| Name | |||
|---|---|---|---|
| Maher MasoudPresident and Chief Executive Officer | |||
| Douglas SwirskyFormer Chief Financial Officer | |||
| Ali SoleymannezhadFormer Chief Commercial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Maxcyte. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board6
See all- Stanley C. ErckDirector · 20 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
- John JohnstonDirector · 9 yr on the boardIndependentAudit—Paid as an executive
- Rekha HemrajaniDirector · 4 yr on the boardIndependentCompensation (Chair)—Paid as an executive
- Yasir Al-WakeelDirector · 4 yr on the boardIndependentAudit—Paid as an executive
- Patrick J. BalthropDirector · 3 yr on the boardIndependentNominating and Corporate Governance (Chair)—Paid as an executive
- Cynthia CollinsDirector · 1 yr on the boardIndependentCompensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Mar 25, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 11, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 12, 2024 | FY2023 |
